Patents Assigned to AVANTI POLAR LIPIDS, INC.
-
Patent number: 10739353Abstract: The present invention includes methods and compositions for ameliorating symptoms or treating one or more adverse reactions triggered by infectious diseases or disease conditions that trigger a widespread release of cytokines in a subject comprising the steps of: identifying the subject in need of amelioration of symptoms or treatment of the infectious diseases or disease conditions that trigger a widespread release of cytokines; and administering one or more pharmaceutical compositions comprising a therapeutically effective amount of a curcumin extract, curcuminoids or synthetic curcumin (S-curcumin) and derivatives thereof, or empty liposomes, dissolved or dispersed in a suitable aqueous or non-aqueous medium sufficient to reduce the level of cytokines in the host.Type: GrantFiled: December 30, 2015Date of Patent: August 11, 2020Assignees: Signpath Pharma, Inc., Avanti Polar Lipids, Inc.Inventors: Peter P. Sordillo, Lawrence Helson, Stephen W. Burgess, Walter A. Shaw
-
Patent number: 10463738Abstract: The present disclosure provides for a composition which may be used for the solublization of an agent or the oral administration of an agent, the composition comprising, a lyosphosphatidyl compound and at least one of a monoglyceride and a free fatty acid. In certain embodiments, the composition comprises a lyosphosphatidyl compound, a monoglyceride and a free fatty acid. In certain embodiments, the composition comprises an agent, a lyosphosphatidyl compound, a monoglyceride and a free fatty acid.Type: GrantFiled: November 8, 2017Date of Patent: November 5, 2019Assignee: Avanti Polar Lipids, Inc.Inventors: Walter A Shaw, Stephen W Burgess, Shengrong Li
-
Patent number: 10143744Abstract: Essentially pure compounds of the formulas (I) to (XX) are provided. Compositions and methods for enhancing or stimulating an immune response are also provided. The compounds, provided are advantageous in that the compounds are essentially pure and free from contaminants encountered when such compounds are purified from natural sources.Type: GrantFiled: January 26, 2016Date of Patent: December 4, 2018Assignees: Avanti Polar Lipids, Inc, AC Immune SAInventors: Walter A Shaw, Stephen W Burgess, Shengrong Li, David T Hickman, Maria Pilar Lopez-Deber
-
Patent number: 9872908Abstract: The present disclosure provides for a composition which may be used for the solublization of an agent or the oral administration of an agent, the composition comprising, a lyosphosphatidyl compound and at least one of a monoglyceride and a free fatty acid. In certain embodiments, the composition comprises a lyosphosphatidyl compound, a monoglyceride and a free fatty acid. In certain embodiments, the composition comprises an agent, a lyosphosphatidyl compound, a monoglyceride and a free fatty acid.Type: GrantFiled: August 10, 2015Date of Patent: January 23, 2018Assignee: Avanti Polar Lipids, Inc.Inventors: Walter A Shaw, Stephen W Burgess, Shengrong Li
-
Patent number: 9518078Abstract: Essentially pure compounds of the formulas (I) to (XXV) are provided. Compositions and methods for enhancing or stimulating an immune response are also provided. The compounds, provided are advantageous in that the compounds are essentially pure and free from contaminants encountered when such compounds are purified from natural sources.Type: GrantFiled: April 12, 2013Date of Patent: December 13, 2016Assignees: Avanti Polar Lipids, Inc., AC Immune SAInventors: Walter A Shaw, Stephen W Burgess, Shengrong Li, David T Hickman, Maria Pilar Lopez-Deber
-
Patent number: 9403760Abstract: Disclosed are compounds of the general formula I and II (as further defined herein) are useful in the production of inhibitors of sphingolipid synthesis the production of sphingolipids. Suitable sphingolipids, include, but not limited to, sphingosine and compounds incorporating sphingosine or that may use sphingosine as an intermediate or a starting material in their synthesis (including, but not limited to, sphingosine-1-P, ceramide, gangliosides and sphingomyelin). In one contemplated use, compounds of the general formula I and II are useful in the production of sphingosine. In another contemplated use, compounds of the general formula I and II are useful in the production of a sphingofugin. Methods of manufacturing each of the above compounds are also provided.Type: GrantFiled: March 14, 2013Date of Patent: August 2, 2016Assignee: AVANTI POLAR LIPIDS, INC.Inventors: Stephen W Burgess, Walter A Shaw, Shengrong Li
-
Patent number: 9241988Abstract: Essentially pure compounds of the formulas (I) to (XX) are provided. Compositions and methods for enhancing or stimulating an immune response are also provided. The compounds, provided are advantageous in that the compounds are essentially pure and free from contaminants encountered when such compounds are purified from natural sources.Type: GrantFiled: March 15, 2013Date of Patent: January 26, 2016Assignees: AVANTI POLAR LIPIDS, INC., AC IMMUNE SAInventors: Walter A Shaw, Stephen W Burgess, Shengrong Li, David T Hickman, Maria Pilar Lopez-Deber
-
Publication number: 20140275591Abstract: Disclosed are compounds of the general formula I and II (as further defined herein) are useful in the production of inhibitors of sphingolipid synthesis the production of sphingolipids. Suitable sphingolipids, include, but not limited to, sphingosine and compounds incorporating sphingosine or that may use sphingosine as an intermediate or a starting material in their synthesis (including, but not limited to, sphingosine-1-P, ceramide, gangliosides and sphingomyelin). In one contemplated use, compounds of the general formula I and II are useful in the production of sphingosine. In another contemplated use, compounds of the general formula I and II are useful in the production of a sphingofugin. Methods of manufacturing each of the above compounds are also provided.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Applicant: Avanti Polar Lipids, Inc.Inventor: Avanti Polar Lipids, Inc.
-
Publication number: 20130273149Abstract: Essentially pure compounds of the formulas (I) to (XX) are provided. Compositions and methods for enhancing or stimulating an immune response are also provided. The compounds, provided are advantageous in that the compounds are essentially pure and free from contaminants encountered when such compounds are purified from natural sources.Type: ApplicationFiled: March 15, 2013Publication date: October 17, 2013Applicants: AC IMMUNE SA, AVANTI POLAR LIPIDS, INC.Inventors: Walter A. SHAW, Stephen W. Burgess, Shengrong Li, David T. Hickman, Maria Pilar Lopez-Deber